Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma
Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma
Active, not recruiting · NCT04270409 · Registry updated 2025-12-12Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell myeloma, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Active, not recruiting | Phase 3 | 2025-12-12 | NCT04270409 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Sanofi | 254 |
9 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Cancer Specialist of North Florida Site Number : 8400011 | Jacksonville | United States | 1 |
| Colorado Blood Cancer Institute Site Number : 8400007 | Denver | United States | 1 |
| Dana Farber Cancer Institute Site Number : 8400001 | Boston | United States | 1 |
| Novant Health Forsyth Medical Center Site Number : 8401015 | Winston-Salem | United States | 1 |
| Presbyterian Hospital Site Number : 8400015 | Charlotte | United States | 1 |
| Tennessee Oncology Site Number : 8400006 | Nashville | United States | 1 |
| UCLA Site Number : 8400010 | Los Angeles | United States | 1 |
| University of Miami Site Number : 8400012 | Miami | United States | 1 |
| ~University of Texas - MD Anderson Cancer Center Site Number : 8400002 | Houston | United States | 1 |